Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed ...

Objective Pancreatic ductal adenocarcinoma (PDAC) is the most lethal malignancy and lacks effective treatment. We aimed to understand molecular mechanisms of the intertwined interactions between ...

Objective Pancreatic ductal adenocarcinoma (PDAC) shows a remarkable predilection for liver metastasis. Pro-oncogenic secretome delivery and trafficking via exosomes are crucial for pre-metastatic ...

Objectives: To investigate the potential value of a contrast enhanced computed tomography (CECT)-based radiological-radiomics nomogram combining a lymph node (LN) radiomics signature and LNs’ ...

Surufatinib plus TAS-102 showed promising survival benefits with manageable toxicity in refractory metastatic PDAC patients, per phase 2 trial data. Data from a phase 2 trial (NCT05481463) presented ...

Data presented at the 2025 ASCO Gastrointestinal Cancer Symposium showed that baseline geriatric assessment (GA) vulnerabilities and quality of life (QOL) scores were associated with overall survival ...

Adding telotristat ethyl to chemotherapy may result in weight stabilization in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and cachexia, according to findings from a phase 2 study ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...